Revelation Biosciences (REVB)
Develops Gemini immunomodulators for acute kidney injury and chronic kidney disease.
Something off on this page? Send us feedback.
Develops Gemini, a PHAD-based innate-immune modulator for acute kidney injury and chronic kidney disease, through GEM-AKI and GEM-CKD. A pre-revenue virtual-development model depends on outsourced clinical and manufacturing work, financing, and a single shared platform.
Develops Gemini, a PHAD formulation designed to modulate innate immune signaling through Toll-like receptor 4. Lead programs are GEM-AKI for patients with established severe acute kidney injury before dialysis and GEM-CKD for chronic kidney disease; an oral formulation is also being explored for repeat dosing.
Operates as a U.S.-based virtual-development organization, using outside manufacturers and clinical vendors rather than internal sales, distribution, or manufacturing. With no approved products or revenue, development is financed through equity and warrant transactions and could ultimately be commercialized through a focused sales capability, pharmaceutical partners, collaborations, or out-licensing.
Both lead programs depend on Gemini and on a single PHAD supplier, a third-party clinical-material manufacturer, and continued performance under its Vanderbilt license.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.5M · Total debt $739.9K · Total assets $12.5M · Shareholders' equity $10.1M
- Revenue
- $0
- Operating income
- −$3.7M
- Net income
- −$3.3M
No dividends on record.
| Insiders7 holders · as of Aug 18, 2026 | 21.51% | 856.8K shares | |
| Strategic holders1 holder · as of May 15, 2026 | 8.11% | 323.2K shares | |
| Otherremainder | 70.38% | 2.80M shares |
3.98M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
James RolkeInsiderdirector, officer: Chief Executive Officer | 10.61% | 422,814 | Form 4filed Aug 18, 2026 ↗ |
Armistice Capital, LLCStrategic | 8.11% | 323,241 | 13Gfiled May 15, 2026 ↗ |
Chester Stanley III ZygmontInsiderofficer: Chief Financial Officer | 7.53% | 300,136 | Form 4filed Aug 18, 2026 ↗ |
Jess RoperInsiderdirector | 1.13% | 44,839 | Form 4filed Aug 18, 2026 ↗ |
Jennifer CarverInsiderdirector | 1.12% | 44,769 | Form 4filed Aug 18, 2026 ↗ |
| See all 24 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- AstraZeneca (ADR)
Farxiga leads broad CKD care, with an adjacent AKI prevention program.
- Eli Lilly
Jardiance is a marketed, broad-CKD disease-progression therapy.
- Novartis (ADR)
Fabhalta targets inflammatory CKD in primary IgA nephropathy.
- Travere Therapeutics
Filspari serves progressive glomerular CKD subgroups.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Revelation Biosciences | $0.9403 | −7.81% | $3.9M | — | — | — | — |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Travere Therapeutics | $67.85 | +0.95% | $6.25B | — | 34.3 | 10.6 | +48.2% |
| Median | 24.5 | 22.8 | 8.1 | +27.0% |